Sunitinib-induced hypothyroidism / 대한내과학회지
Korean Journal of Medicine
;
: 506-508, 2010.
Article
in Korean
| WPRIM
| ID: wpr-219497
ABSTRACT
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor that is effective for advanced renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. Currently, sunitinib is being investigated in multiple other tumor types including non-small cell lung cancer, breast cancer, colon cancer, and endocrine tumors. Recent studies have shown that sunitinib induces thyroid dysfunction, mainly hypothyroidism during treatment. The incidence of sunitinib-induced hypothyroidism has been reported to be 36~85%. Although several hypotheses have been suggested, the mechanisms by which sunitinib induces hypothyroidism are not clear. As considered the fairly high incidence of sunitinib-induced hypothyroidism, thyroid function should be regularly monitored in all patients treated with sunitinib.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pyrroles
/
Thyroid Gland
/
Protein-Tyrosine Kinases
/
Breast Neoplasms
/
Carcinoma, Renal Cell
/
Incidence
/
Colonic Neoplasms
/
Carcinoma, Non-Small-Cell Lung
/
Gastrointestinal Stromal Tumors
/
Hypothyroidism
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS